Agenus to Present at Cambridge Healthtech Institute’s Second Annual Conference on Immunomodulatory Therapeutic Antibodies f...
August 04 2014 - 7:00AM
Business Wire
Agenus Inc. (Nasdaq:AGEN), an immuno-oncology company developing
a portfolio of checkpoint modulators (CPMs), heat shock protein
vaccines and adjuvants, today announced that Robert Stein, MD, PhD,
the company’s Chief Scientific Officer, will speak at Cambridge
Healthtech Institute‘s Second Annual Conference on Immunomodulatory
Therapeutic Antibodies For Cancer. Dr. Stein will give a
presentation on the topic “Humanized Monoclonal Antibodies as
Agonists for GITR or OX40 Signaling” in a session of the meeting
entitled “Immune Modulatory Targets for Antibody Therapeutics” at
the Marriott Long Wharf Hotel in Boston, MA on Monday, August 11th
at 4:00 pm ET.
About Agenus
Agenus is an immuno-oncology company developing a portfolio of
checkpoint modulators (CPMs), heat shock protein vaccines and
adjuvants. Agenus’ checkpoint modulator programs target GITR, OX40,
CTLA-4, LAG-3, TIM-3 and PD-1, critical targets in co-stimulatory
and inhibitory pathways regulating self-tolerance and immune
responses to tumor antigens. Checkpoint modulators represent an
important new class of cancer immunotherapeutics. The company’s
proprietary discovery engine, Retrocyte Display,® is used to
generate fully human and humanized therapeutic antibody drug
candidates. The Retrocyte Display platform uses a high-throughput
approach incorporating IgG format human antibody libraries
expressed in mammalian B-lineage cells. Agenus’ Prophage heat shock
protein vaccines recently generated positive data in phase 2
studies in newly diagnosed gliobastoma (the most common and most
aggressive malignant primary brain cancer) and in genital herpes
(an incurable infectious disease afflicting approximately 40
million adults in the United States). The company’s QS-21 Stimulon®
adjuvant is a key component in the development of several
investigational vaccines across a wide variety of infectious
diseases and therapeutic vaccines intended to treat cancer and
degenerative disorders. The QS-21 platform is extensively partnered
with GlaxoSmithKline and Janssen and includes two candidates in
phase 3 trials for melanoma and shingles. A regulatory application
was filed recently by GlaxoSmithKline with the EMA, and has been
accepted for review, following positive results in a phase 3 trial
in malaria. For more information, please visit www.agenusbio.com,
or connect with the company on Facebook, LinkedIn, Twitter and
Google+. For more information, please visit www.agenusbio.com.
Forward-Looking Statement
This press release contains forward-looking statements,
including statements regarding the Company’s upcoming corporate
presentation. These forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others,
the factors described under the Risk Factors section of our
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission for the period ended June 30, 2014. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this document, and Agenus
undertakes no obligation to update or revise the statements. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement. Agenus’ business is subject
to substantial risks and uncertainties, including those identified
above. When evaluating Agenus’ business and securities, investors
should give careful consideration to these risks and
uncertainties.
BMC CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024